Harjeet Singh, Ph.D.
Department of Pediatrics, Division of Pediatrics
Present Title & Affiliation
Dual/Joint/Adjunct Appointment
Assistant Professor, Department of Pediatrics - Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Postgraduate Training
| 2006-2008 | Postdoctoral Fellow, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2004-2006 | Research Fellowship, City of Hope Cancer Center & Beckman Research Institute, Duarte, California |
| 2002-2004 | Research Fellowship, City of Hope Cancer Center & Beckman Research Institute, Duarte, California |
Experience & Service
Faculty Academic Appointments
Instructor, Department of Pediatrics - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - 2019
Other Professional Positions
Research Investigator, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - 2016
Intramural Institutional Committee Activities
Immunology Program Admission Sub-Committee, Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, 2024 - 2025
Extramural Institutional Committee Activities
Immunology Program Admission Committee, Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, 2025 - Present
Member, Pebbles Task Force (Pediatrics), The University of Texas MD Anderson Cancer Center, 2023 - Present
Team Leader, Pediatrics Stem Cell Transplantation & Immunotherapy Multidisciplinary Team, The University of Texas MD Anderson Cancer Center, 2021 - Present
Team Leader, Non-neural Solid Tumor Multidisciplinary Team, The University of Texas MD Anderson Cancer Center, 2021 - Present
Senator, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2019 - 2025
Member, Capital Equipment Committee (Pediatrics Research), The University of Texas MD Anderson Cancer Center, 2019 - Present
Member, Research Animal Care Committee (RACC), City of Hope/Beckman Research Institute, 2005 - 2006
Editorial Activities
Associate Editor, Cancer Immunity and Immunotherapy, 2021 - Present
Review Editor, Frontiers in Immunology, 2016 - Present
Review Editor, Frontiers in Oncology, 2016 - Present
Honors & Awards
| 2013 | Performance Award for Dedication and Teamwork, The University of Texas MD Anderson Cancer Center |
| 2010 | Performance Award for Mentoring, The University of Texas MD Anderson Cancer Center |
| 2008 | Kimberly Patterson Fellowship in Leukemia Research |
| 2008 | Travel Award, World Imaging Congress |
| 2008 | Bristol-Myers Squibb Poster Award, The University of Texas MD Anderson Cancer Center |
| 2006 | New Investigator Travel Grant, BMT Tandem Meetings |
| 2006 | Travel Award, American Society of Hematology |
| 2005 | Developmental Research Grant Award, City of Hope Lymphoma Spore |
| 2003 | J Mitra Memorial Award, Indian Journal of Gastroenterology |
| 2001 | Best Paper Award, Indian National Association for Study of the Liver |
| 1999 | Best Poster Award, Symposium Biological Chemistry Beyond 2000 |
Professional Memberships
Selected Presentations & Talks
National Presentations
- 2019. Genetic modification of T cells to express CD19-specific CAR in two days. Conference. Genetic modification of T cells to express CD19-specific CAR in two days. San Francisco, CA, US.
- 2018. Sleeping Beauty: An update on the non-viral transduction platform for CAR therapies. Conference. Sleeping Beauty: An update on the non-viral transduction platform for CAR therapies. San Francisco, CA, US.
- 2015. Engineering T cells for one and all. Conference. Engineering T cells for one and all. Boston, MA, US.
- 2015. Democratizing gene therapy through the genetic manipulation of T cells. Conference. Democratizing gene therapy through the genetic manipulation of T cells. West Palm Beach, FL, US.
- 2015. The commercialization of T-cell therapies. Conference. The commercialization of T-cell therapies. Houston, TX, US.
- 2012. Reprogramming of T cells for improved therapeutic potential. Conference. Reprogramming of T cells for improved therapeutic potential. Lost Pines, TX, US.
- 2009. Genetically Engineered CD56-specific T Cells for the Treatment of Recurrent Neuroblastoma. Poster. National Harbor, MD, US.
- 2006. Non-invasive PET imaging of T cells derived from umbilical cord blood. Conference. Non-invasive PET imaging of T cells derived from umbilical cord blood. Keystone, CO, US.
- 2005. Combining Immunocytokine With Adoptive Immunotherapy To Treat B-Lineage Lymphomas. Conference. Combining Immunocytokine With Adoptive Immunotherapy To Treat B-Lineage Lymphomas. Atlanta, GA, US.
- 2003. Contribution of BCR Y177 ABL C-Terminal Sequences to BCR/ABL-Induced Transformation of Human Hematopoietic Progenitors. Conference. Contribution of BCR Y177 ABL C-Terminal Sequences to BCR/ABL-Induced Transformation of Human Hematopoietic Progenitors. San Diego, CA, US.
International Presentations
- 2015. The right patient for the right therapy. Conference. The right patient for the right therapy. Mainz, DE.
Formal Peers
- 2019. Reprogramming T cells for enhanced persistence. Invited. Houston, TX, US.
Grant & Contract Support
| Date: | 2024 - 2029 |
| Title: | attIL12 modified TIL transfer for enhanced tumor infiltration in autologous liposarcoma PDX tumors |
| Funding Source: | NIH/R01 |
| Role: | PI |
| ID: | PA-20-185 |
| Date: | 2023 - 2025 |
| Title: | Bi-specific CAR T cells for AML |
| Funding Source: | Institutional Research Grant Program Award 2023 |
| Role: | PI |
| ID: | 2023-00062775-Y1 |
| Date: | 2022 - 2023 |
| Title: | Allogeneic umbilical cord blood derived gamma delta CAR T cells for pediatric malignancies |
| Funding Source: | Hyundai Hope on Wheels |
| Role: | CO-I |
| Date: | 2021 - 2022 |
| Title: | Gamma-delta T cells for pediatric malignancies |
| Funding Source: | Pediatrics Research--Team Project SCT |
| Role: | Co-PI |
| Date: | 2021 - 2022 |
| Title: | Gamma Delta T cell Therapy for Pediatric Brain Tumors |
| Funding Source: | Matthew Larson Foundation |
| Role: | PI |
| Date: | 2020 - 2021 |
| Title: | Targeting Neoantigens in Pediatric Sarcoma |
| Funding Source: | QuadW Foundation |
| Role: | CO-I |
| Date: | 2019 - 2022 |
| Title: | NK cell Therapy for Refractory or Relapsed Osteosarcoma |
| Funding Source: | UTMDACC Multidisciplinary Research Program |
| Role: | CO-I |
| Date: | 2018 - 2020 |
| Title: | Engineering T cells to overcome tumor resistance a |
| Funding Source: | Pediatric Cancer Research Foundation |
| Role: | PI |
| Date: | 2017 - 2022 |
| Title: | Qualitative single-cell biomarkers of T-cell biomarkers of T-cell metabolism for predictable immunotherapy |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| Date: | 2017 - 2020 |
| Title: | Balancing T-cell function and metabolism for immunotherapy |
| Funding Source: | Department of Defense (DOD) |
| Role: | CO-I |
| Date: | 2017 - 2020 |
| Title: | Biomanufacturing next generation T cells |
| Funding Source: | National Science Foundation (NSF) |
| Role: | CO-I |
| Date: | 2017 - 2022 |
| Title: | Dual-targeting Chimeric Antigen Receptor Immunotherapy for Glioblastoma |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| Date: | 2008 |
| Title: | The Kimberly Patterson Fellowship in Leukemia Research |
| Funding Source: | Kimberly Patterson Fellowship |
| Role: | Project Leader |
| Date: | 2007 |
| Title: | Analyses of Hematopoietic Cellular Components Derived from Umbilical Cord Blood-Propagate and Evaluate tumor-specific umbilical cord blood-derived T cells |
| Funding Source: | JP McCarthy Fund |
| Role: | CO-I |
| Date: | 2005 |
| Title: | Evaluating role of CD20-ICK in T Cell persistence and its synergistic role in treating B-lymphoma |
| Funding Source: | City of Hope Lymphoma Spore |
| Role: | Project Leader |
| Title: | Gamma delta CAR T cells for Osteosarcoma |
| Funding Source: | Children's Oncology Group, Enzo and Me Pediatric Cancer Foundation Grant for Pediatric Osteosarcoma |
| Role: | CO-I |
| Title: | Off-the-shelf bi-specific CAR T cells for Acute Myeloid Leukemia |
| Funding Source: | Children’s Cancer Research Foundation |
| Role: | PI |
Selected Publications
Peer-Reviewed Articles
- Hu J, Singh H, Jin Y, Zhang W, Wang J, Xia X, Somaiah N, Gorlick R, Li S. Collagen-disrupting attIL12 TIL therapy boosts deep T cell infiltration via dual signaling activation and CCKAR reduction in sarcomas. Proc Natl Acad Sci U S A 122(41):e2507542122, 2025. e-Pub 2025. PMID: 41052334.
- Kumaresan P, Maiti S, Hauser PJ, Roszik J, Singh H, Dhamne C. Isolation and expansion of clinical grade T regulatory cells for GvHD prophylaxis. Int J Clin Transl Med 1(3):4, 2025. e-Pub 2025.
- Rezvan A, Romain G, Fathi M, Heeke D, Martinez-Paniagua, An X, Bandey IN, Montalvo MJ, Adolacion JRT, Saeedi A, Sadeghi F, Fousek K, Puebla-Osorio N, Cooper LJN, Bernatchez C, Singh H, Ahmed N, Mattie M, Bot A, Neelapu S, Varadarajan N. Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling. Nat Cancer 5(7):1010-1023, 2024. e-Pub 2024. PMID: 38750245.
- Bandey I, Montalvo M, Singh H, Varadarajan N. Overcoming migratory exhaustion: Expression of Matrix metalloproteinase-8 (MMP-8) promotes tumor infiltration and anti-tumor activity of CAR-T cells. bioRxiv, 2023. e-Pub 2023.
- Singh, H, Srour, S, Milton, D, McCarty, J, Dai, C, Gaballa, MM, Ammari, M, Olivares, S, Huls, H, de Groot, E, Marin, D, Petropoulos, D, Olson, AL, Anderlini, P, Im, JS, Khouri, IF, Hosing, C, Rezvani, K, Champlin, RE, Shpall, E, Cooper, L, Kebriaei, P. Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies. Front Immunol 13, 2022. e-Pub 2022. PMID: 36439104.
- Romain G, Strati P, Rezvan A, Fathi M, Bandey IN, Adolacion JR, Heeke DS, Liadi I, Marques-Piubelli ML, Solis Soto LM, Mahendra A, Vega F, Cooper LJ, Singh H, Mattie M, Bot A, Neelapu S, Varadarajan N. Multidimensional single-cell analysis identifies a role for CD2-CD58 interactions in clinical antitumor T cell responses. J Clin Invest 132(17), 2022. e-Pub 2022. PMID: 35881486.
- Tambaro FP, Singh H, Jones E, Rytting M, Mahadeo KM, Thompson P, Daver N, DiNardo C, Kadia T, Garcia-Manero G, Chan T, Shah RR, Wierda WG. Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia. Leukemia 35(11):3282-3286, 2021. e-Pub 2021. PMID: 33833386.
- Srour, S, Singh, H, McCarty, J, de Groot, E, Huls, H, Rondon, G, Qazilbash, MH, Ciurea, SO, Bardelli, G, Buck, J, Alousi, AM, Nieto, Y, Rezvani, K, Marin, D, Popat, UR, Hosing, C, Shpall, E, Wierda, WG, Kantarjian, HM, Champlin, RE, Cooper, L, Kebriaei, P. Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas. Blood 135(11):862-865, 2020. e-Pub 2020. PMID: 31961918.
- Liadi I, Singh H, Romain G, Roysam B, Cooper LJ, Varadarajan N. Defining potency of CAR+ T cells: Fast and furious or slow and steady. Oncoimmunology 8(10):e1051298, 2019. e-Pub 2019. PMID: 31646063.
- Lu H, Li J, Martinez M, Bandey I, Amritkar A, Singh H, Mayerich D, Varadarajan V, Roysam B. TIMING 2.0: high-throughput single-cell profiling of dynamic cell-cell interactions by time-lapse imaging microscopy in nanowell grids. Bioinformatics 35(4):706-708, 2019. e-Pub 2019. PMID: 30084956.
- Crossland DL, Denning WL, Ang S, Olivares S, Mi T, Switzer K, Singh H, Hulus H, Gold KS, Glisson BS, Cooper LJ, Heymach JV. Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models. Oncogene 37(27):3686-3697, 2018. e-Pub 2018. PMID: 29622795.
- Hurton LV, Singh H, Najjar AM, Switzer KC, Mi T, Maiti S, Olivares S, Rabinovich B, Huls H, Forget MA, Datar V, Kebriaei P, Lee DA, Champlin RE, Cooper LJ. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc Natl Acad Sci U S A 113(48):E7788-E7797, 2016. e-Pub 2016. PMID: 27849617.
- Kebriaei P, Singh H, Huls MH, Figliola MJ, Bassett R, Olivares S, Jena B, Dawson MJ, Kumaresan PR, Su S, Maiti S, Dai J, Moriarity B, Forget MA, Senyukov V, Orozco A, Liu T, McCarty J, Jackson RN, Moyes JS, Rondon G, Qazilbash M, Ciurea S, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Kantarjian H, Keating M, Wierda W, Do KA, Largaespada DA, Lee DA, Hackett PB, Champlin RE, Cooper LJ. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest 126(9):3363-76, 2016. e-Pub 2016. PMID: 27482888.
- Thokala R, Olivares S, Mi T, Maiti S, Deniger D, Huls H, Torikai H, Singh H, Champlin RE, Laskowski T, McNamara G, Cooper LJ. Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors. PLoS One 11(8):e0159477, 2016. e-Pub 2016. PMID: 27548616.
- Caruso HG, Torikai H, Zhang L, Maiti S, Dai J, Do KA, Singh H, Huls H, Lee DA, Champlin RE, Heimberger AB, Cooper LJ. Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor. J Immunother 39(5):205-17, 2016. e-Pub 2016. PMID: 27163741.
- Merouane A, Rey-Villamizar N, Lu Y, Liadi I, Romain G, Lu J, Singh H, Cooper LJ, Varadarajan N, Roysam B. Automated profiling of individual cell-cell interactions from high-throughput time-lapse imaging microscopy in nanowell grids (TIMING). Bioinformatics 31(19):3189-97, 2015. e-Pub 2015. PMID: 26059718.
- Caruso HG, Hurton LV, Najjar A, Rushworth D, Ang S, Olivares S, Mi T, Switzer K, Singh H, Huls H, Lee DA, Heimberger AB, Champlin RE, Cooper LJ. Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity. Cancer Res 75(17):3505-18, 2015. e-Pub 2015. PMID: 26330164.
- Krishnamurthy J, Rabinovich BA, Mi T, Switzer KC, Olivares S, Maiti SN, Plummer JB, Singh H, Kumaresan PR, Huls HM, Wang-Johanning F, Cooper LJ. Genetic Engineering of T Cells to Target HERV-K, an Ancient Retrovirus on Melanoma. Clin Cancer Res 21(14):3241-51, 2015. e-Pub 2015. PMID: 25829402.
- Deniger DC, Yu J, Huls MH, Figliola MJ, Mi T, Maiti SN, Widhopf GF, Hurton LV, Thokala R, Singh H, Olivares S, Champlin RE, Wierda WG, Kipps TJ, Cooper LJ. Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations. PLoS One 10(6):e0128151, 2015. e-Pub 2015. PMID: 26030772.
- Liadi I, Singh H, Romain G, Rey-Villamizar N, Merouane A, Adolacion JR, Kebriaei P, Huls H, Qiu P, Roysam B, Cooper LJ, Varadarajan N. Individual Motile CD4(+) T Cells Can Participate in Efficient Multikilling through Conjugation to Multiple Tumor Cells. Cancer Immunol Res 3(5):473-82, 2015. e-Pub 2015. PMID: 25711538.
- Kumaresan PR, Manuri PR, Albert ND, Maiti S, Singh H, Mi T, Roszik J, Rabinovich B, Olivares S, Krishnamurthy J, Zhang L, Najjar AM, Huls MH, Lee DA, Champlin RE, Kontoyiannis DP, Cooper LJ. Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. Proc Natl Acad Sci U S A 111(29):10660-5, 2014. e-Pub 2014. PMID: 25002471.
- Singh H, Figliola MJ, Dawson MJ, Olivares S, Zhang L, Yang G, Maiti S, Manuri P, Senyukov V, Jena B, Kebriaei P, Champlin RE, Huls H, Cooper LJ. Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells. PLoS One 8(5):e64138, 2013. e-Pub 2013. PMID: 23741305.
- Deniger DC, Switzer K, Mi T, Maiti S, Hurton L, Singh H, Huls H, Olivares S, Lee DA, Champlin RE, Cooper LJ. Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor. Mol Ther 21(3):638-47, 2013. e-Pub 2013. PMID: 23295945.
- Huls MH, Figliola MJ, Dawson MJ, Olivares S, Kebriaei P, Shpall EJ, Champlin RE, Singh H, Cooper LJ. Clinical application of Sleeping Beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood. J Vis Exp(72):e50070, 2013. e-Pub 2013. PMID: 23407473.
- Maiti SN, Huls H, Singh H, Dawson M, Figliola M, Olivares S, Rao P, Zhao YJ, Multani A, Yang G, Zhang L, Crossland D, Ang S, Torikai H, Rabinovich B, Lee DA, Kebriaei P, Hackett P, Champlin RE, Cooper LJ. Sleeping beauty system to redirect T-cell specificity for human applications. J Immunother 36(2):112-23, 2013. e-Pub 2013. PMID: 23377665.
- Jena B, Maiti S, Huls H, Singh H, Lee DA, Champlin RE, Cooper LJ. Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials. PLoS One 8(3):e57838, 2013. e-Pub 2013. PMID: 23469246.
- Denman CJ, Senyukov VV, Somanchi SS, Phatarpekar PV, Kopp LM, Johnson JL, Singh H, Hurton L, Maiti SN, Huls MH, Champlin RE, Cooper LJ, Lee DA. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One 7(1):e30264, 2012. e-Pub 2012. PMID: 22279576.
- Jin Z, Maiti S, Huls H, Singh H, Olivares S, Mátés L, Izsvák Z, Ivics Z, Lee DA, Champlin RE, Cooper LJ. The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor. Gene Ther 18(9):849-56, 2011. e-Pub 2011. PMID: 21451576.
- Singh H, Figliola MJ, Dawson MJ, Huls H, Olivares S, Switzer K, Mi T, Maiti S, Kebriaei P, Lee DA, Champlin RE, Cooper LJ. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res 71(10):3516-27, 2011. e-Pub 2011. PMID: 21558388.
- Davies JK, Singh H, Huls H, Yuk D, Lee DA, Kebriaei P, Champlin RE, Nadler LM, Guinan EC, Cooper LJ. Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies. Cancer Res 70(10):3915-24, 2010. e-Pub 2010. PMID: 20424114.
- Manuri PV, Wilson MH, Maiti SN, Mi T, Singh H, Olivares S, Dawson MJ, Huls H, Lee DA, Rao PH, Kaminski JM, Nakazawa Y, Gottschalk S, Kebriaei P, Shpall EJ, Champlin RE, Cooper LJ. piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Hum Gene Ther 21(4):427-37, 2010. e-Pub 2010. PMID: 19905893.
- Singh H, Manuri PR, Olivares S, Dara N, Dawson MJ, Huls H, Hackett PB, Kohn DB, Shpall EJ, Champlin RE, Cooper LJ. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res 68(8):2961-71, 2008. e-Pub 2008. PMID: 18413766.
- Chu S, Li L, Singh H, Bhatia R. BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia. Cancer Res 67(14):7045-53, 2007. e-Pub 2007. PMID: 17638918.
- Singh H, Serrano LM, Pfeiffer T, Olivares S, McNamara G, Smith DD, Al-Kadhimi Z, Forman SJ, Gillies SD, Jensen MC, Colcher D, Raubitschek A, Cooper LJ. Combining adoptive cellular and immunocytokine therapies to improve treatment of B-lineage malignancy. Cancer Res 67(6):2872-80, 2007. e-Pub 2007. PMID: 17363611.
- Ramaraj P, Singh H, Niu N, Chu S, Holtz M, Yee JK, Bhatia R. Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors. Cancer Res 64(15):5322-31, 2004. e-Pub 2004. PMID: 15289338.
- Agarwal N, Naik S, Aggarwal R, Singh H, Somani SK, Kini D, Pandey R, Choudhuri G, Saraswat VA, Naik SR. Occult hepatitis B virus infection as a cause of cirrhosis of liver in a region with intermediate endemicity. Indian J Gastroenterol 22(4):127-31, 2003. e-Pub 2003. PMID: 12962434.
- Singh H, Aggarwal R, Singh RL, Naik SR, Naik S. Frequency of infection by hepatitis B virus and its surface mutants in a northern Indian population. Indian J Gastroenterol 22(4):132-7, 2003. e-Pub 2003. PMID: 12962435.
- Singh H, Pradhan M, Singh RL, Phadke S, Naik SR, Aggarwal R, Naik S. High frequency of hepatitis B virus infection in patients with beta-thalassemia receiving multiple transfusions. Vox Sang 84(4):292-9, 2003. e-Pub 2003. PMID: 12757503.
Review Articles
- Greenbaum U, Yalniz FF, Srour SA, Rezvani K, Singh H, Olson A, Jr BG, Hong DS, Shpall EJ, Kebriaei P. Chimeric Antigen Receptor Therapy: How Are We Driving in Solid Tumors?. Biol Blood Marrow Transplant 26(10):1759-1769, 2020. e-Pub 2020. PMID: 32623078.
- Kebriaei P, Izsvák Z, Narayanavari SA, Singh H, Ivics Z. Gene Therapy with the Sleeping Beauty Transposon System. Trends Genet 33(11):852-870, 2017. e-Pub 2017. PMID: 28964527.
- Singh H, Moyes JS, Huls MH, Cooper LJ. Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor. Cancer Gene Ther 22(2):95-100, 2015. e-Pub 2015. PMID: 25591810.
- Singh H, Huls H, Kebriaei P, Cooper LJ. A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunol Rev 257(1):181-90, 2014. e-Pub 2014. PMID: 24329797.
Professional Educational Materials
- Singh H. Development, generation and implementation of Standard Operating Procedures (SOPs) and Worksheets for GLP and cGMP procedures required for generation of Chimeric Antigen Receptor modified T-cells, 2016.
Other Articles
- Rezvan, A, Romain, G, Fathi, M, Heeke, D, Martinez Paniagua, M, An, X, Bandey, I, Montalvo, MJ, Adolacion, JR, Saeedi, A, Sadeghi, F, Fousek, K, Puebla-Osorio, N, Cooper, L, Bernatchez, C, Singh, H, Ahmed, NM, Mattie, M, Bot, A, Neelapu, SS, Varadarajan, N Author Correction: Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling. Nat Cancer 5(6):954, 2024. PMID: 38778179.
Abstracts
- Zhang ZT, Zhang WD, Zhou X, Longo C, Wang YF, Mao DX, Yi YH, Xu Zh, Li Z, Olivares S, Jusu S, Singh H, Roth M, Gill J, Al-Lazikani, Gorlick R. Acquired cell adhesion molecule 1 (CADM1) ADC resistance model for optimizing payload efficacy and toxicity in osteosarcoma preclinical testing. Cancer Res 85((8_Supplement_1)):1716, 2025. e-Pub 2025.
- Menon P, Kumar M, Singh H, Bandey I, Varadarajan N. Reprogramming the tumor microenvironment endowing T and NK cells with the ability to degrade the extracellular matrix. J Immunother Cancer 12((Suppl 2)):A401-A401, 2024. e-Pub 2024.
- Olivares S, Hernandez FN, Zhang W, Zhang Z, Gorlick R, Singh H. Effective targeting of osteosarcoma by ex vivo expanded TCR γδ T cells. J Immunother Cancer 12((Suppl 2)):A1-A1683, 2024. e-Pub 2024.
- Zhou X, Zhou X, Beird H, Beird H, Yi YH, Yi YH, Xu ZH, Xu ZH, Zhang ZT, Zhang ZT, Singh H, Singh H, Zhang WD, Zhang WD, Wang YF, Wang YF, Jusu S, Jusu S, Roth M, Roth M, Gill J, Gill J, Gorlick R, Gorlick R. Modeling and genomic profiling of osteosarcoma development in murine chondrocyte-origin models. Cancer Res 84((6_Supplement)):139, 2024. e-Pub 2024.
- Olivares S, Hernandez F, Zhang W, Gordon N, Gopalakrishnan V, Gill J, Gorlick R, Singh H. Ex vivo expanded tumor-infiltrating lymphocytes for sarcoma treatment. Connective Tissue Oncology Society Annual Meeting, 2023. e-Pub 2023.
- Hernandez F, Jawed J, Olivares S, Mahadeo KM, Singh H. Gamma Delta T Cells for Acute Myeloid Leukemia. Blood 140 (Supplement 1): 12696, 2022. e-Pub 2022.
- Rezvan A, Romain G, Fathi M, Heeke D, Martinez-Paniagua M, An X, Bandey IN, Liadi I, Cooper LJN, Singh H, Bot A, Neelapu S, Varadarajan N. Multiomic dynamic single-cell profiling of CAR T cell populations associated with efficacy. J Immunol 208((1_Supplement)):54.18, 2022. e-Pub 2022.
- Bandey I, Adolacion JRT, Romain G, Martinez M, An XY, Saeedi A, Rajanayke R, Liadi I, Singh H, Cooper L, Varadarajan N. Designed improvement to T-cell immunotherapy by integrated single cell profiling. J Immunother Cancer 9(3), 2021. e-Pub 2021. PMID: 33722906.
- Hurton LV, Mi T, Switzer KC, Zhang L, Cuiping D, Kim M, Bavisi KR, Figliola MJ, Vazquez LM, Maiti S, Su S, Deniger DC, Olivares S, Cooper LJN, Singh H. Rapid Personalized Manufacture (RPM) of Sleeping Beauty System-generated NY-ESO-1-specific TCR-T Cells Co-expressing Membrane-bound IL-15 Yields Antitumor Responses. Blood 134 (Supplement_1):3218, 2019. e-Pub 2019.
- An X, Romain G, Martinez-Paniagua M, Bandey IN, Adolacion JRT, Fathi M, Liadi I, Sadeghi F, Mahendra A, Amritkar A, Roysam B, Singh H, Cooper LJ, Varadarajan N. CAR+ T cell anti-tumor efficacy revealed by multi-dimensional single-cell profiling. J Immunol 202 (1_Supplement): 134.2, 2019. e-Pub 2019.
- Tejada FNH, Najjar A, Guerrero AD, Flores LG, Singh H. ROR1-specific CAR for neuroblastoma using sleeping beauty-modified t cells. Journal of Clinical Oncology 36(15):10523, 2018. e-Pub 2018.
- Kebriaei P, Huls H, Neel S, Olivares S, Orozco A, Su S, Maiti S, Smith A, De Groot E, Kantarjan H, Ohanian M, Rezvani K, Shpall EJ, Champlin R, Cooper LJ, Singh H. Shortening the Time to Manufacture CAR(+) T Cells with Sleeping Beauty System Supports T-Cell Engraftment and Anti-Tumor Effects in Patients with Refractory CD19(+) Tumors. Blood Volume 130, Supplement 1, 2017. e-Pub 2017.
- Kebriaei P, Huls H, Olivares S, Orozco AF, Su S, Maiti S, De Groot E, Smith A, Yang Y, Rondon G, Qazilbash M, Ciurea S, Alousi A, Nieto Y, Marin D, Popat U, Hosing C, Kantarjian H, Rezvani K, Shpall EJ, Champlin R, Cooper LJ, Singh H. Long Term Follow up after Adoptive Transfer of CD19-Specific CAR+ T Cells Genetically Modified Via Non-Viral Sleeping Beauty S ystem Following Hematopoietic Stem Cell Transplantation (HSCT). Blood Volume 130, Supplement 1, 2017. e-Pub 2017.
- Hurton LV, Singh H, Switzer KC, Tiejuan M, Flores LG, Orozco A, Maiti SN, Su S, Najjar A, Huls MH, Kebriaei P, Champlin RE, Cooper LJ. Very Rapid Production of CAR+ T-Cells upon Non-Viral Gene Transfer Using the Sleeping Beauty System. Blood 128 (22): 2807, 2016. e-Pub 2016.
- Patel K, Olivares S, Singh H, Hurton LV, Huls MH, Qazilbash MH, Kebriaei P, Champlin RE, Cooper LJ. Combination Immunotherapy with NY-ESO-1-Specific CAR+ T cells with T-cell Vaccine Improves Anti-Myeloma Effect. Blood 128 (22): 3366, 2016. e-Pub 2016.
- Romain G, Singh H, Liad I, Adolacion JR, Cooper LJN, Varadarajan N. Migratory T cells demonstrate superior persistence and enhanced tumor control. Cancer Immunol Res 4 (11_Supplement): B082, 2016. e-Pub 2016.
- Singh H. Next-generation non-viral gene transfer to redirect T-cell specificity. Mol Ther 24 (Suppl) 1(276):S110, 2016. e-Pub 2016.
- Kebriaei P, Ciurea SO, Huls MH, Singh H, Olivares S, Su S, Figliola MJ, Kumar P, Jena B, Forget MA, Ang S, Jackson R, Liu T, McNiece IK, Rondon G, Hackett P, Kantarjian HM, Lee DA, Popat UR, Alousi A, Oran B, Shah N, Hosing CM, Marin D, Rezvani K, Shpall EJ, Champlin RE. Pre-Emptive Donor Lymphocyte Infusion with CD19-Directed, CAR-Modified T Cells Infused after Allogeneic Hematopoietic Cell Transplantation for Patients with Advanced CD19+ Malignancies. Blood 126(23):862, 2015. e-Pub 2015.
- Kebriaei P, Huls H, Singh H, Olivares S, Figliola M, Maiti S, Su SH, Kumar PR, Jena B, Forget MA, Ang S, Rineka J, Liu TT, McNiece IK, Rondon G, Hackett P, Wierda WG, O'Brien S, Keating MJ, Kantarjian HM, Hosing CM, Shpall EJ, Champlin RE, Cooper LJN. Adoptive Therapy Using Sleeping Beauty Gene Transfer System and Artificial Antigen Presenting Cells to Manufacture T Cells Expressing CD19-Specific Chimeric Antigen Receptor. Blood 124(21):311, 2014. e-Pub 2014.
- Varadarajan N, Ivan L, Gabrielle R, Singh H, Cooper LJN, Amin M. Functional and molecular characterization of single serial killer CAR+ T cells demonstrates adaptive modification of behavior and fate based on tumor cell density. J Immunother Cancer 2(Suppl 3): P145, 2014. e-Pub 2014.
- Hurton LV, Switzer K, Singh H, Forget MA, Mi TJ, Maiti S, Olivares S, Champlin RE, Lee DA, Cooper LJN. Tethered IL-15 on CD19-Specific T Cells Sustains Long-Term Persistence and Promotes a Stem Cell Memory-Like Phenotype. Molecular Therapy 22(Supplement 1):S242, 2014. e-Pub 2014.
- Kumaresan PR, Manuri PR, Albert ND, Singh H, Rabinovich B, Krishnamurthy J, Maiti SN, Simon O, Mi TJ, Lee D, Kontoyiannis D, Huls H, Cooper LJN. Dual-Specificity CAR plus T Cells to Target B-Cell Malignancies and Opportunistic Fungal Infection. Biology of Blood and Marrow Transplantation 20(2):S132, 2014. e-Pub 2014.
- Singh H, Liadi I, Romain G, Varadarajan N, Cooper LJN. Evaluating the Effector Function of Individual CD19-Specific T Cells to Assess the Therapeutic Impact of a Manufactured Product. Biology of Blood and Marrow Transplantation 20(2):S134-S135, 2014. e-Pub 2014.
- Kebriaei P, Huls H, Singh H, Olivares S, Figliola M, Kumar PR, Jena B, Jackson RN, Liu TT, McNiece IK, Rondon G, Hackett P, Champlin RE, Shpall EJ, Cooper LJN. Adoptive Immunotherapy Following Umbilical Cord Blood Transplantation Using The Sleeping Beauty System and Artificial Antigen Presenting Cells To Generate Donor-Derived T Cells Expressing a CD19-Specific Chimeric Antigen Receptor. Blood 122(21):4208, 2013. e-Pub 2013.
- Krishnamurthy J, Rabinovich B, Olivares S, Mi T, Switzer K, Plummer J, Maiti S, Singh H, Huls H, Johanning FW, Cooper LJN. Targeting An Ancient Retrovirus In Tumor Using Engineered T Cells. Blood 122(21):4206, 2013. e-Pub 2013.
- Kebriaei P, Huls H, Singh H, Olivares S, Figliola M, Kumar PR, Jena B, Forget MA, Ang S, Jackson RN, Liu TT, Bosque D, McNiece IK, Rondon G, Hackett P, Hosing CM, Shpall EJ, Champlin RE, Cooper LJN. First Clinical Trials Employing Sleeping Beauty Gene Transfer System and Artificial Antigen Presenting Cells To Generate and Infuse T Cells Expressing CD19-Specific Chimeric Antigen Receptor. Blood 122(21):166, 2013. e-Pub 2013.
- Hurton LV, Switzer K, Singh H, Forget MA, Mi T, Olivares S, Champlin RE, Lee DA, Cooper LJN. Tethered IL-15 Mutein on CD19-Specific T Cells Sustains Persistence When Tumor Antigen Is Low and Can Treat Minimal Residual Disease. Molecular Therapy 21(1):S237, 2013. e-Pub 2013.
- Kebriaei P, Huls H, Singh H, Olivares S, Figliola MJ, Dawson M, Jena B, Jackson R, Bosque D, McNiece I, Rondon G, Hackett PB, Shpall EJ, Champlin RE, Cooper LJN. First-in-Human Application of Sleeping Beauty System for Gene Therapy. Molecular Therapy 21(1):S4, 2013. e-Pub 2013.
- Singh H, Liadi I, Romain G, Varadarajan N, Cooper LJN. Single-Cell Imaging Reveals That Subsets of T Cells Expressing a CD19-Specific Chimeric Antigen Receptor Differ in Effector Function. Molecular Therapy 21(Supplement 1):S151, 2013. e-Pub 2013.
- Deniger DC, Kipps TH, Olivares S, Singh H, Maiti S, Hurton LV, Switzer KC, Mi TJ, Thokala R, Huls H, Wierda WG, Cooper LJN. Clinical Implications of ROR1-Specific T Cells That Target B-Cell Leukemia. Molecular Therapy 21(Supplement 1):S194, 2013. e-Pub 2013.
- Thokala R, Switzer K, Juan MT, Olivares S, Singh H, Huls H, Champlin RE, Cooper LJN. Re-Directing T Cells with Chimeric Antigen Receptors To Target CD123+ Leukemia. Molecular Therapy 21(Supplement 1):S247-S248, 2013. e-Pub 2013.
- Varadarajan N, Liadi I, Romain G, Singh H, Cooper LJN. Quantitative single-cell functional characterization of CD19-specific CAR+ T Cells for immunotherapy. Cancer Res 73(8_Supplement):4745, 2013. e-Pub 2013.
- Singh H, Gibbons HN, Olivares S, Figliola MJ, Dawson MJ, Huls MH, Lee DA, Kebriaei P, Champlin RE, Cooper LJN. Third Generation Chimeric Antigen Receptors Containing CD137 or CD134 Signaling Endodomains Augment CD19-Specific T-Cell Effector Function. Blood 114(22):4097, 2009. e-Pub 2009.
- Denman CJ, Kopp LM, Senyukov V, Hagemeister S, Johnson J, Da Silva MAL, Singh H, Hurton L, Olivares S, Huls MH, Champlin RE, Cooper LJN, Lee DA. Sustained Ex Vivo Expansion of Human Peripheral Blood NK Cells Using Artificial APCs Bearing Membrane-Bound IL-21. Blood 114(22):3030, 2009. e-Pub 2009.
- Hurton LV, Singh H, Olivares S, Ang SO, Kelly SS, Kebriaei P, Lee DA, Champlin RE, Cooper LJN. IL-7 as a Membrane-Bound Molecule for the Costimulation of Tumor-Specific T Cells. Blood 114(22):3035, 2009. e-Pub 2009.
- Manuri PR, Maiti SN, Singh H, Mi TJ, Olivares S, Dawson MJ, Huls H, Lee DA, Rao PH, Kaminski JM, Kebriaei P, Wilson MH, Cooper LJN. PiggyBac, an Efficient Method for Genetic Modification of T Cells with Second Generation CD19-Specific Chimeric Antigen Receptor (CAR) for Treatment of B-Lineage Malignancies. Molecular Therapy 17(Supplement 1):S212-S213, 2009. e-Pub 2009.
- Maiti SN, Moriarity B, Rao P, Zhao YJ, Dawson M, Olivares S, Figliola M, Zhang L, Huls H, Manuri P, Singh H, Jin ZM, Largaespada DA, Hackett P, Kebriaei P, Champlin R, Cooper LJN. In Depth Analysis of Sleeping Beauty Transposition for Therapeutic Gene Therapy Using CD19-Specificic T Cells. Molecular Therapy 17(Supplement 1):S92, 2009. e-Pub 2009.
- Singh H, Huls MH, Dawson MJ, Mi T, Lee DA, Kebriaei P, Shpall EJ, Hackett PB, June CH, Champlin RE, Cooper LJN. Selective Reprogramming of CD19-Specific T Cells with IL-21 and CD28 Signaling For Adoptive Immunotherapy of Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation 15(2, Supplement):61-62, 2009. e-Pub 2009.
- Davies JK, Singh H, Yuk D, Champlin RE, Nadler LM, Guinan EC, Cooper LJN. To Augment A GVL Effect and Reduce GVHD: Alloreactivity of Human CD19-Specific T Cells can be Reduced by Alloanergization without Reduction of Tumor-Specific Killing. Biology of Blood and Marrow Transplantation 15(2, Supplement):121, 2009. e-Pub 2009.
Letters to the Editor
- Hurton LV, Siddik RI, Singh H, Olivares S, Rabinovich BA, Tian R, Mojsilovic D, Hildebrand W, Lee DA, Kelly SS, Champlin R, Shpall EJ, Fernandez-Viña M, Cooper LJ. Identifying candidate allogeneic NK-cell donors for hematopoietic stem-cell transplantation based on functional phenotype. Leukemia 24: 1059-62, 2010.
- Singh H, Najjar AM, Olivares S, Nishii R, Mukhopadhyay U, Alauddin M, Manuri PR, Huls H, Lee DA, Dotti G, Bollard C, Simmons PJ, Shpall EJ, Champlin RE, Gelovani JG, Cooper LJ. PET imaging of T cells derived from umbilical cord blood. Leukemia 23: 620-2, 2009.
- Numbenjapon T, Serrano LM, Singh H, Kowolik CM, Olivares S, Gonzalez N, Chang WC, Forman SJ, Jensen MC, Cooper LJ. Characterization of an artificial antigen-presenting cell to propagate cytolytic CD19-specific T cells. Leukemia 20: 1889-1892, 2006.
Patient Reviews
CV information above last modified March 06, 2026